Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
about
Gastrin and Gastric Cancer.Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion.Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma.Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma.Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections.Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findingsSerum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.Rebound hypersecretion after inhibition of gastric acid secretion.Malignant Range Elevation of Serum Chromogranin A due to Inadvertent Use of Proton Pump Inhibitor in a Subject with Pancreatic IncidentalomaDiagnosis of Zollinger-Ellison syndrome: increasingly difficult.Pancreatic neuroendocrine tumors: biology, diagnosis,and treatmentInhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.Effects of Helicobacter pylori infection and long-term proton pump inhibitor use on enterochromaffin-like cells.From bench to bedside: chromogranin B-a promising novel biomarker in heart failure.Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan.Sunitinib malate as first-line treatment for an advanced, poorly differentiated pancreatic neuroendocrine tumor.Proton-pump inhibitors: understanding the complications and risks.Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman.Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.Circulating EM66 is a highly sensitive marker for the diagnosis and follow-up of pheochromocytoma.Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.Neuroendocrine in Barrett's mucosa and adenocarcinomas of the gastroesophageal junction.Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity.Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.Effect of proton-pump inhibitor therapy on serum chromogranin a level.Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial
P2860
Q30238683-0A20C52A-CAE8-42F3-8CB9-D802548422BDQ34394118-C8CAD088-4F81-4491-B56D-7D584115D5F5Q35009459-7D122013-78C4-4651-BFBA-7FF9BCA3C0E5Q35011372-FF5CC0F5-2C43-4A71-A0A6-4C48DD377995Q35093730-E0CB77F6-3617-4910-8D49-758D6914B7DAQ35194532-83CB5102-F0FE-47FF-909D-2393B34DA9F1Q35557414-3382DBE7-6EC9-41A6-8E95-1203EA375CDFQ35603973-872C0F2B-EE44-4637-922A-159360584509Q35713515-274270B8-23D4-4138-A8D9-048E2F10711FQ35763890-06F7C98B-21D5-49C0-9DDF-F8E29FCAAA94Q36169134-502B7180-4AE9-4924-9E99-21502180BD1EQ36351873-488B24CC-7530-49FD-985B-CD197F88AAB2Q37354131-1952BF11-53CA-4C97-A265-1DCC6F038851Q37520340-2B30BB7D-E37D-46E1-8027-27336721DFE2Q37647361-0F61F517-1214-40CD-A1EE-24D09E3B3E1CQ37959070-F9827208-0AD6-4261-85A3-A3B2DDE09A7EQ38931272-3A361D7F-6778-4C3E-8610-000F40090FD5Q39411115-8EB45302-DB33-44B6-8402-68DC09822B48Q41996131-E5F94534-97E5-425A-8D84-D1BF2C76EA22Q42270405-48AB18F9-6E1F-4AB5-B0E4-188C921442B8Q42473648-009723B9-F1DF-471C-A4DC-D5161C3975B5Q42861897-CB807F00-5A94-46FA-8198-A70785B10666Q43120420-08975CBE-0560-4BAC-9923-FA0129C2A652Q46803225-EF1D2926-AF1B-4E48-95FB-96854B5A740FQ46946129-0134CBFF-73BB-4BB2-9FE4-2CE764E7B00BQ47404152-565A462B-8657-47EE-BD26-4756AE378AFDQ47668183-122798A9-0CCA-4DDC-BE94-979CCFDDA1E3Q48263186-8FB29432-86B4-4C74-AB5E-FD31DF85F637Q50075239-1E9C581E-DE97-419B-9849-F421CF7B7DB4Q51379787-DA3723A6-83BC-47A7-BE5C-114B67C96CDDQ51430102-642BD5EC-FC45-4FE2-9A25-3DCCA0814DD3Q51438737-B5D5F35A-24BA-480F-91D8-8F1DEA8C9E53Q58003581-09E80268-96CB-487E-B1FD-54804A029BDF
P2860
Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@en
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@nl
type
label
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@en
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@nl
prefLabel
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@en
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@nl
P2093
P2860
P1476
Serum chromogranin A as a scre ...... ring acid-suppressive therapy.
@en
P2093
De Bruïne A
Hameeteman W
Lundqvist G
Sanduleanu S
Stockbrügger RW
Stridsberg M
P2860
P304
P356
10.1046/J.1365-2362.2001.00890.X
P577
2001-09-01T00:00:00Z